News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,796 Results
Type
Article (13573)
Company Profile (110)
Press Release (247113)
Section
Business (87955)
Career Advice (461)
Deals (15333)
Drug Delivery (63)
Drug Development (36525)
Employer Resources (49)
FDA (6259)
Job Trends (6183)
News (150045)
Policy (14011)
Tag
Academia (435)
Alliances (23080)
Alzheimer's disease (347)
Approvals (6250)
Artificial intelligence (58)
Bankruptcy (143)
Best Places to Work (4307)
Biosimilars (39)
Biotechnology (44)
Breast cancer (40)
Cancer (286)
Career advice (405)
Cell therapy (39)
Clinical research (30330)
Collaboration (129)
Compensation (55)
COVID-19 (746)
C-suite (49)
Data (290)
Diabetes (47)
Diagnostics (1230)
Drug pricing (56)
Earnings (31456)
Employer resources (43)
Events (36643)
Executive appointments (145)
FDA (6422)
Funding (91)
Gene therapy (58)
GLP-1 (289)
Government (1264)
Healthcare (3518)
Infectious disease (763)
Inflammatory bowel disease (45)
Interviews (58)
IPO (5808)
Job creations (2050)
Job search strategy (372)
Layoffs (166)
Legal (3410)
Lung cancer (44)
Manufacturing (85)
Medical device (1260)
Medtech (1262)
Mergers & acquisitions (9544)
Metabolic disorders (154)
Neuroscience (436)
NextGen Class of 2024 (1580)
Non-profit (589)
Northern California (388)
Obesity (96)
Opinion (108)
Patents (51)
People (28409)
Pharmaceutical (64)
Phase I (7886)
Phase II (12824)
Phase III (11529)
Pipeline (134)
Podcasts (39)
Policy (43)
Postmarket research (1399)
Preclinical (3161)
Radiopharmaceuticals (116)
Rare diseases (82)
Real estate (2629)
Regulatory (9805)
Research institute (562)
Resumes & cover letters (55)
Southern California (398)
Startups (1624)
United States (3907)
Vaccines (110)
Weight loss (76)
Date
Last 7 days (335)
Last 30 days (1028)
Last 365 days (12627)
2024 (11103)
2023 (14262)
2022 (19569)
2021 (20073)
2020 (19033)
2019 (14887)
2018 (11714)
2017 (13893)
2016 (13130)
2015 (15473)
2014 (12421)
2013 (10593)
2012 (11396)
2011 (11922)
2010 (10889)
Location
Africa (312)
Arizona (39)
Asia (19755)
Australia (2552)
California (907)
Canada (560)
China (100)
Connecticut (37)
Europe (38742)
Florida (130)
Illinois (102)
Indiana (81)
Kansas (51)
Maryland (146)
Massachusetts (802)
Minnesota (50)
New Jersey (384)
New York (251)
North Carolina (269)
Northern California (388)
Pennsylvania (267)
South America (498)
Southern California (398)
Texas (122)
Virginia (37)
Washington State (66)
260,796 Results for "stada pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters
Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster bone drugs Prolia and Xgeva.
June 11, 2024
·
2 min read
·
Nick Paul Taylor
Business
Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® medicines for osteoporosis and cancer-related bone loss respectively.
June 11, 2024
·
11 min read
Business
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health.
June 11, 2024
·
4 min read
Business
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera Solutions (688177:SH) and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® (golimumab).
May 28, 2024
·
5 min read
Drug Development
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.
January 10, 2024
·
11 min read
Press Releases
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
July 22, 2024
·
11 min read
Pharm Country
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
NEXGEL, Inc. announced a partnership with STADA Arzneimittel AG, a European leader in consumer health, to distribute and commercialize consumer health OTC products in North America in 2024.
December 11, 2023
·
2 min read
Policy
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
Partners STADA and Alvotech announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency has adopted a positive opinion for Uzpruvo, a biosimilar candidate to Stelara®.
November 10, 2023
·
10 min read
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU
Partners STADA and Calliditas Therapeutics AB announced the submission of a request to the European Medicines Agency for the Committee for Medicinal Products for Human Use to convert the conditional marketing authorization for Kinpeygo®, their treatment for primary IgA nephropathy, to standard, or “full”, marketing authorization.
September 28, 2023
·
3 min read
Policy
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
Calliditas Therapeutics AB, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of full marketing authorisation for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy.
May 30, 2024
·
4 min read
1 of 26,080
Next